1 / 20

Tony Gershlick University Hospitals of Leicester UK

PROTECT TRIAL. Tony Gershlick University Hospitals of Leicester UK. Speaker Bureau, Advisory Board, Recipient Research Grants Medtronic Vascular. Bare metal stent (n=878). Bare metal stent (n=1,757). CYPHER stent (n=870). TAXUS stent (n=1,749). 0. 0. 1. 1. 2. 2. 3. 3. 4. 4.

garrison-jennings
Télécharger la présentation

Tony Gershlick University Hospitals of Leicester UK

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PROTECT TRIAL Tony Gershlick University Hospitals of Leicester UK

  2. Speaker Bureau, Advisory Board, Recipient Research Grants Medtronic Vascular

  3. Bare metal stent (n=878) Bare metal stent (n=1,757) CYPHER stent (n=870) TAXUS stent (n=1,749) 0 0 1 1 2 2 3 3 4 4 Independent CRF patient-level meta-analysisFreedom From Death or Myocardial Infarction RAVEL, SIRIUS, E-SIRIUS, C-SIRIUS (n=1,748) TAXUS I, II, IV, V, VI (n=3,506) 89.7% (88) 88.2% (182) P=0.39 P=0.77 88.4% (100) 87.6% (186) Time after Initial Procedure (years) Time after Initial Procedure (years) Conclusion : No clinical difference in outcome out to 4 years

  4. Freedom From (Protocol) Stent Thrombosis RAVEL, SIRIUS, E-SIRIUS, and C-SIRIUS (n=1,748) TAXUS I, II, IV, V, VI (n=3,506) 99.4% (5) 99.1% (14) P=0.20 P=0.29 98.8% (10) 98.7% (20) Bare metal stent (n=878) Bare metal stent (n=1,757) CYPHER stent (n=870) TAXUS stent (n=1,749) 4 4 0 1 2 3 0 1 2 3 Time after Initial Procedure (years) Time after Initial Procedure (years) Independent CRF patient-level meta-analysis

  5. 99.1% (14) P=0.29 98.7% (20) 99.4% (5) P=0.20 98.8% (10) After 1 year After 1 year 9vs. 2, P=0.033 5vs. 0, P=0.025 Variation in Definitions Bare metal stent (n=878) Bare metal stent (n=1,757) CYPHER stent (n=870) TAXUS stent (n=1,749) 0 0 1 1 2 2 3 3 4 4 Freedom From (Protocol) Stent Thrombosis RAVEL, SIRIUS, E-SIRIUS, and C-SIRIUS (n=1,748) TAXUS I, II, IV, V, VI (n=3,506) Time after Initial Procedure (years) Time after Initial Procedure (years) No clinical sequelae

  6. Definite or Probable : Cypher versus Velocity Definite or Probable : Endeavor versus Driver New (ARC) Definitions Sirolimus-Eluting - - - - - Bx Velocity - - - - - ENDEAVOR - - - - - Driver - - - - - 1.5%versus1.7% p= 0.70 0.5%versus1.4% p= 0.06

  7. Need for • Long term adequately powered trial • Handle on whether any one stent presents less of a risk

  8. All patients who you currently now treat

  9. CYPHER & ENDEAVOR on shelf • @ up to 100+50 patients / site • UK ~ 2000 - 3500 /8800 patients • Trial time-lines • Finalisation protocol Current • Ethics • Ist patient projected • Interim analysis • trial duration 3 years • Subgroup studies UK : APT compliance PROTECT –AMI & the UK

  10. In Conclusion : PROTECT-AMI - a large, important study with significant UK input – READY TO GO !!!

More Related